MedImmune has received approval from the FDA for FluMist Quadrivalent (intranasal, live influenza vaccine) for prevention of influenza. FluMist Quadrivalent is the first four-strain influenza vaccine approved by the FDA.

All other currently available seasonal influenza vaccines are trivalent, containing three strains (two strains of type A influenza and one B lineage strain). FluMist Quadrivalent contains four strains (two strains of type A and two type B lineages) to help provide broad protection. Clinical studies showed a safety profile and immunogenicity generally comparable to the trivalent FluMist formulations. Further, the addition of the second B strain did not result in immune interference to other strains included in the vaccine.

FluMist Quadrivalent is a vaccine that is sprayed into the nose to help protect against influenza. It can be used in children, adolescents, and adults ages 2–49.   

For more information visit